Find on this page scientific articles about important studies and trials using Hiltonol®
A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease.
Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.
Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: First report on clinical effectiveness, quality of life, and adverse events.
Poly-ICLC, a multi-functional immune modulator for treating cancer.
Double-stranded RNA immunomodulators in prostate cancer
Orygen Biotecnologia Ltda
Avenida Brigadeiro Faria Lima, 4509 | 16º andar, conjunto 163 | Vila Nova Conceição
São Paulo | CEP 04538-132